Dapagliflozin (Farxiga): Uses, Dosage, Side Effects & Monito

Medical Disclaimer: This information is for educational purposes only. Always consult your healthcare provider before starting, stopping, or changing any medication.

What This Medicine Does

Dapagliflozin (brand name Farxiga) is an SGLT2 inhibitor that works in a unique way - it helps your kidneys remove excess sugar from your body through your urine.

How it works:

1. Normally: Your kidneys filter sugar from blood but reabsorb almost all of it back into your body
2. With dapagliflozin: It blocks the SGLT2 protein, preventing sugar reabsorption so excess sugar is removed in your urine
3. The result: Lower blood sugar without needing extra insulin

Bonus benefits discovered:

• Helps protect your heart (reduces heart failure hospitalizations and cardiovascular death)
• Slows kidney disease progression
• May lead to modest weight loss (2-3 kg average)
• Can slightly lower blood pressure

What makes it different: Unlike many diabetes medicines, dapagliflozin's heart and kidney benefits work even if you don't have diabetes. It's now prescribed for heart failure and chronic kidney disease regardless of diabetes status.

---

What to Expect: A Timeline

Day 1-3: Getting Started

You'll notice:

• Increased urination - This is expected and shows the medicine is working
• Mild thirst - Drink plenty of water
• Possible sugar in urine - Your urine may test positive for sugar (this is normal with this medicine)

This effect decreases over time as your body adjusts.

Week 1-2: Settling In

• Blood sugar levels start improving
• Urination frequency normalizes
• You may notice slight weight loss (water weight initially)

Month 1-3: Ongoing Benefits

• Improved HbA1c levels (0.7-1.2% reduction average)
• Possible continued modest weight loss
• Blood pressure may decrease slightly
• Heart and kidney protection begins

Long-Term: Protection

• Heart benefits accumulate over months to years
• Kidney protection continues as long as you take the medicine
• Cardiovascular risk reduction sustained in long-term studies

---

Common Things You Might Notice

Increased Urination (Very Common - Especially at First)

• Why: The medicine causes sugar to leave in your urine, which pulls water with it (osmotic diuresis)
• When: Most noticeable in the first week
• What to do: Drink plenty of water, plan bathroom access
• Good news: This effect lessens over time

Genital & Urinary Issues

• Yeast infections - More common in women; can also affect men (balanitis)
• Urinary tract infections - Slightly increased risk
• What to watch: Burning, itching, unusual discharge, pain with urination

Other Common Effects

• Mild thirst or dry mouth
• Slight nausea (rare)
• Weakness or fatigue (especially if also taking diuretics)
• Back pain (some reports)

---

Sick Day Rules: Very Important!

Dapagliflozin can increase your risk of a dangerous condition called euglycemic DKA (diabetic ketoacidosis with normal blood sugar). This is rare but serious.

When to Temporarily Stop This Medicine

STOP taking dapagliflozin and contact your doctor if:

• You're vomiting more than twice in 6 hours
• You have diarrhea for more than 24 hours
• You can't eat or drink normally
• You have a fever above 101°F (38.3°C)
• You're having surgery (stop 3-4 days before, as directed by your doctor)
• You're having a medical test with contrast dye
• You're doing intense physical activity or fasting
• You're under significant physical stress

What is Euglycemic DKA?

Unlike typical DKA, your blood sugar may be normal or only slightly elevated even though your body is producing ketones. This can fool you into thinking everything is fine.

Symptoms to watch for:

• Nausea, vomiting, abdominal pain
• Rapid, deep breathing
• Confusion or difficulty concentrating
• Fruity breath odor
• Unusual tiredness

If you have these symptoms, seek immediate care and mention you take dapagliflozin.

---

When to Call Your Doctor

Seek Immediate Care For:

• Severe abdominal pain, nausea, or vomiting
• Rapid breathing or shortness of breath
• Confusion, difficulty concentrating
• Fruity breath odor
• Severe genital pain, swelling, or redness (especially in the groin area)
• Signs of Fournier's gangrene (rare but serious)

Contact Your Doctor Soon For:

• Symptoms of yeast infection (itching, discharge, redness)
• Burning or pain with urination
• Fever or signs of infection
• Significant weight loss or weakness
• Dizziness or fainting (could indicate dehydration)
• Dark-colored urine

---

Hygiene & Prevention Tips

Preventing Genital Infections

1. Stay clean and dry - Wash and dry the genital area thoroughly daily
2. Wear breathable clothing - Cotton underwear, loose-fitting clothes
3. Change quickly - Don't stay in wet swimsuits or sweaty clothes
4. Urinate after sex - Helps prevent UTIs
5. Stay hydrated - Drink plenty of water to flush bacteria
6. Consider probiotics - May help maintain healthy bacteria balance

Preventing UTIs

1. Drink water - Aim for 6-8 glasses daily
2. Don't hold it - Urinate when you feel the urge
3. Wipe front to back - Helps prevent bacteria spread
4. Shower, don't soak - Avoid long baths if prone to UTIs
5. Urinate after intercourse - Helps flush bacteria

---

Practical Daily Tips

1. Take in the morning - Most people take it with breakfast; taking earlier in the day means more bathroom visits happen while you're awake

2. Stay hydrated - Especially important when starting dapagliflozin

3. Wear light pads - For women, some mild urine leakage is possible initially

4. Plan bathroom access - Especially in the first week, be prepared for more frequent trips

5. Track your symptoms - Note any infections, side effects, or changes to discuss with your doctor

6. Have a sick day plan - Know when to stop the medicine and when to call for help

7. Monitor for infections - Pay attention to genital and urinary symptoms

---

Food & Medicine Interactions

Diuretics ("Water Pills")

• Interaction: Increased risk of dehydration and low blood pressure
• Examples: Furosemide, hydrochlorothiazide
• What to do: Monitor for dizziness; your doctor may adjust doses

Blood Pressure Medicines

• Interaction: May further lower blood pressure
• Examples: ACE inhibitors, ARBs, beta-blockers
• What to do: Monitor for dizziness, especially when standing up quickly

Insulin or Sulfonylureas

• Interaction: May need dose reduction to avoid low blood sugar
• Examples: Insulin glargine, glipizide, glyburide
• What to do: Your doctor may adjust these medicines when starting dapagliflozin

---

For Healthcare Professionals

Clinical Information

Pharmacology & Mechanism

Dapagliflozin selectively inhibits sodium-glucose cotransporter 2 (SGLT2) in the proximal renal tubules, blocking reabsorption of filtered glucose and causing glucosuria. This results in:

• Reduced blood glucose independent of insulin secretion or action
• Osmotic diuresis (natriuresis and calciuresis)
• Modest blood pressure reduction (3-5 mmHg systolic)
• Weight loss through calorie excretion (~200-300 calories/day)
• Hemodynamic benefits (reduced preload and afterload)
• Improved tubuloglomerular feedback, reducing intraglomerular pressure

Available Dosing

Dapagliflozin (Farxiga):

• Starting dose: 5 mg once daily
• Target dose: 10 mg once daily
• Maximum dose: 10 mg once daily
• Renal adjustment: Discontinue if eGFR ＜25 mL/min/1.73m²
• Administration: Once daily, morning preferred, with or without food

FDA-Approved Indications:

• Type 2 diabetes mellitus (as monotherapy or add-on)
• Heart failure with reduced ejection fraction (HFrEF)
• Heart failure with preserved ejection fraction (HFpEF)
• Chronic kidney disease (CKD) to reduce CKD progression
• Cardiovascular risk reduction in patients with T2D and established CVD

Monitoring Requirements

Baseline:

• eGFR, serum creatinine
• Potassium (if on ACEI/ARB or risk factors)
• Urinalysis (if history of GU infections)
• Ketone testing capability if at risk for DKA

Follow-up:

• Renal function (eGFR) periodically
• Volume status assessment
• Signs/symptoms of GU infections at each visit
• Ketones during acute illness or DKA symptoms
• HbA1c every 3 months

Expected Lab Changes:

• Small eGFR dip (~3-5 mL/min/1.73m²) is expected initially, then stabilizes
• Small hematocrit increase (due to hemoconcentration)
• Small phosphate increase
• Albuminuria reduction over time

Contraindications & Warnings

Contraindications:

• Severe renal impairment (eGFR ＜25 mL/min/1.73m²)
• Dialysis patients
• Type 1 diabetes mellitus
• History of serious hypersensitivity to dapagliflozin
• Active genital mycotic infections

Warnings & Precautions:

• Ketoacidosis - Euglycemic DKA reported; assess for ketones in metabolic acidosis even if blood glucose ＜250 mg/dL
• Volume depletion - Can cause hypotension, especially in elderly, on diuretics, or with low BP; assess volume status before initiating
• Urogenital infections - Increased risk of mycotic and bacterial infections; monitor and treat
• Necrotizing fasciitis of perineum (Fournier's gangrene) - Rare but serious; prompt treatment required
• Acute kidney injury - Risk increased with volume depletion, hypotension, or concomitant nephrotoxic agents
• Hypoglycemia - Risk increased when combined with insulin or sulfonylureas; consider lowering dose
• Necrotizing fasciitis - Rare but serious; discontinue if suspected
• Bladder cancer - Risk observed in clinical trials; consider benefit-risk in patients with history or active bladder cancer

Drug Interactions

Special Populations

Pregnancy: Category C - avoid, especially second and third trimesters (may affect renal development)

Breastfeeding: Not recommended (limited data, potential for adverse effects)

Geriatric: Increased risk of volume depletion, UTIs, falls from hypotension; assess renal function more frequently

Renal Impairment:

• eGFR ≥30 mL/min/1.73m²: No dose adjustment needed
• eGFR 25-29 mL/min/1.73m²: Use not recommended for glycemic control; may be used for HF/CKD indications
• eGFR ＜25 mL/min/1.73m²: Contraindicated

Hepatic Impairment: No dose adjustment needed for mild-moderate; limited data in severe hepatic impairment

Sick Day Rules for Patients

TEMPORARILY DISCONTINUE if:

• Acute illness causing significant reduced oral intake
• Vomiting ＞2 episodes in 6 hours or diarrhea ＞24 hours
• Fever ＞101°F (38.3°C)
• Scheduled surgery or procedures with contrast (discontinue 3-4 days prior)
• Extreme physical exertion or fasting

RESTART when:

• Oral intake resumes and illness resolves
• 48-72 hours after surgery/procedure
• Clinician approves

Efficacy Data

Glycemic Control:

• HbA1c reduction: 0.7-1.2% as monotherapy or add-on therapy
• Fasting plasma glucose: -20 to -30 mg/dL reduction
• Effect independent of insulin secretion or action

Cardiovascular Outcomes:

• DECLARE-TIMI 58: 27% reduction in HF hospitalization; 17% reduction in CV death/HF hospitalization composite in patients with T2D and established CVD or multiple risk factors
• DAPA-HF: 30% reduction in CV death/HF hospitalization in HFrEF patients (including non-diabetics)
• DELIVER: 18% reduction in CV death/HF hospitalization in HFpEF patients

Kidney Outcomes:

• DAPA-CKD: 39% reduction in sustained eGFR decline ≥50%, ESKD, or renal/CV death in CKD patients with or without T2D
• Consistent benefit across eGFR subgroups (down to 25 mL/min/1.73m²)
• Significant reduction in albuminuria

Weight Loss:

• Modest: 2-3 kg average loss over 6-12 months
• Primarily from calorie excretion via glucosuria

Blood Pressure:

• Systolic BP reduction: 3-5 mmHg average
• Diastolic BP reduction: 1-2 mmHg average

---

---

References

1. FDA Dapagliflozin Prescribing Information. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/

2. McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019;381(21):1995-2008. https://doi.org/10.1056/NEJMoa1911303

3. Wiviott SD, et al. Dapagliflozin in Patients with Type 2 Diabetes and Established Cardiovascular Disease. New England Journal of Medicine. 2019;380(4):347-357. https://doi.org/10.1056/NEJMoa1812389

4. Heerspink HJL, et al. Dapagliflozin in Patients with Chronic Kidney Disease. New England Journal of Medicine. 2020;383(15):1436-1446. https://doi.org/10.1056/NEJMoa2024816

5. American Diabetes Association Professional Practice Committee. Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024;47(Supplement_1):S1-S488. https://doi.org/10.2337/dc24-SINT

6. Perkovic V, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. New England Journal of Medicine. 2019;380(24):2295-2306. https://doi.org/10.1056/NEJMoa1811744

7. Kosiborod MN, et al. Effect of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients with Heart Failure and Reduced Ejection Fraction. Circulation. 2021;143(12):1176-1188. https://doi.org/10.1161/CIRCULATIONAHA.120.051224

8. McMurray JJV, et al. Dapagliflozin in Heart Failure with Preserved Ejection Fraction (DELIVER). New England Journal of Medicine. 2022;387(12):995-1006. https://doi.org/10.1056/NEJMoa2206616

---

Medical Disclaimer: This content is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication.